{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:48:22Z","timestamp":1782197302129,"version":"3.54.5"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The addition of targeted therapy and immunotherapy has significantly improved survival in ovarian cancer patients. This analysis aimed to investigate the adverse events associated with targeted and immunotherapy drugs in patients with ovarian cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Adverse event reports related to bevacizumab, poly (ADP-ribose) polymerase (PARP) inhibitors, and immune checkpoint inhibitors (ICI: PD-1, PD-L1, CTLA-4 inhibitors) in ovarian cancer were sourced from the FDA Adverse Event Reporting System (FAERS) database (Q3 2014 to Q3 2025). The disproportionality analysis, including the reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural network (BCPNN), was employed to detect safety signals associated with different drugs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 209,920 adverse event reports were included in the analysis, involving 33,538 ovarian cancer patients. Among adverse events associated with the target drug (n = 183,935), 157,470 (85.61%) reports were related to PARP inhibitors, followed by bevacizumab [21,001 (11.42%)], PD-1 inhibitors [3,702 (2.01%)], PD-L1 inhibitors [1,317 (0.72%)], and CTLA-4 inhibitors [425 (0.23%)]. Adverse events are most frequently reported within 30 days of taking the medication. The most frequently reported safety signals at the preferred term level associated with PARP inhibitors included Energy increased, Vitamin D decreased, Nocturia, Intentional underdose, Hunger, and Brain neoplasm. For bevacizumab, the most frequently reported safety signals were Gastrointestinal perforation, Proteinuria, Intestinal perforation, and Embolism. For ICI, the most frequently reported safety signals comprised Product use in unapproved indication, Off label use, Death, and Malignant neoplasm progression. The most frequently reported safety signals linked to combination therapy using different drugs vary. For the combination of bevacizumab and PARP inhibitors, the most frequently reported safety signals included Interstitial lung disease, Myelodysplastic syndrome, Myelosuppression, Acute myeloid leukaemia, and Proteinuria.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study systematically analyzed the safety signals related to different drugs during the treatment of ovarian cancer, which may assist clinicians in identifying drug alert signals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1867038","type":"journal-article","created":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:19:02Z","timestamp":1782195542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Adverse events associated with targeted therapy and immunotherapy for ovarian cancer: a FAERS pharmacovigilance study"],"prefix":"10.3389","volume":"17","author":[{"given":"Kui","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongling","family":"Peng","sequence":"additional","affiliation":[{"name":"Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University","place":["Chengdu, China"]},{"name":"Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education","place":["Chengdu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1136\/ijgc-2019-001041","article-title":"Decision analysis for secondline maintenance treatment of platinum sensitive recurrent ovarian cancer: a review","volume":"30","author":"Arend","year":"2020","journal-title":"Int. J. Gynecol. Cancer"},{"key":"B2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"Jama"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1038\/s41467-020-15315-8","article-title":"Immunogenomic profiling determines responses to combined PARP and PD-1 inhibition in ovarian cancer","volume":"11","author":"F\u00e4RKKIL\u00e4","year":"2020","journal-title":"Nat. Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","article-title":"Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy","volume":"434","author":"Farmer","year":"2005","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/s41571-024-00937-4","article-title":"Immunotherapy for ovarian cancer: towards a tailored immunophenotype-based approach","volume":"21","author":"Ghisoni","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.ygyno.2022.05.020","article-title":"OVARIO phase II trial of combination niraparib plus bevacizumab maintenance therapy in advanced ovarian cancer following first-line platinum-based chemotherapy with bevacizumab","volume":"166","author":"Hardesty","year":"2022","journal-title":"Gynecol. Oncol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.annonc.2025.11.020","article-title":"Durvalumab with carboplatin\/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer","volume":"37","author":"Harter","year":"2025","journal-title":"Ann. Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"04101","DOI":"10.7189\/jogh.13.04101","article-title":"Understanding and reporting odds ratios as rate-ratio estimates in case-control studies","volume":"13","author":"Kerr","year":"2023","journal-title":"J. Glob. Health"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1038\/s43018-023-00617-9","article-title":"Clinical and translational advances in ovarian cancer therapy","volume":"4","author":"Konstantinopoulos","year":"2023","journal-title":"Nat. Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"4768","DOI":"10.1200\/jco.23.00529","article-title":"Atezolizumab combined with Bevacizumab and platinum-based therapy for platinum-sensitive ovarian cancer: Placebo-controlled randomized phase III ATALANTE\/ENGOT-ov29 trial","volume":"41","author":"Kurtz","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1016\/s1470-2045(18)30786-1","article-title":"Exploring and comparing adverse events between PARP inhibitors","volume":"20","author":"Lafargue","year":"2019","journal-title":"Lancet Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3322\/caac.21559","article-title":"Epithelial ovarian cancer: evolution of management in the era of precision medicine","volume":"69","author":"Lheureux","year":"","journal-title":"CA Cancer J. Clin."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/s0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer","volume":"393","author":"Lheureux","year":"","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1001\/jamaoncol.2019.3343","article-title":"Assessment of combined nivolumab and bevacizumab in relapsed ovarian cancer: a phase 2 clinical trial","volume":"5","author":"Liu","year":"2019","journal-title":"JAMA Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"viii36","DOI":"10.1093\/annonc\/mdx450","article-title":"Front-line therapy of advanced epithelial ovarian cancer: standard treatment","volume":"28","author":"Marth","year":"2017","journal-title":"Ann. Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"16061","DOI":"10.1038\/nrdp.2016.61","article-title":"Ovarian cancer","volume":"2","author":"Matulonis","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B21","doi-asserted-by":"publisher","first-page":"102945","DOI":"10.1016\/j.ctrv.2025.102945","article-title":"Optimal bevacizumab treatment strategy in advanced ovarian cancer: a review","volume":"137","author":"Monk","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/ppo.0000000000000556","article-title":"Development of next-generation Poly(ADP-Ribose) polymerase 1-Selective inhibitors","volume":"27","author":"Ngoi","year":"2021","journal-title":"Cancer J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/ph14010004","article-title":"Improved detection criteria for detecting drug-drug interaction signals using the proportional reporting ratio","volume":"14","author":"Noguchi","year":"2020","journal-title":"Pharm. (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-023-00970-w","article-title":"PARP inhibitors in ovarian cancer: a review","volume":"18","author":"O'Malley","year":"2023","journal-title":"Target Oncol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1093\/jnci\/djy071","article-title":"Invasive epithelial ovarian cancer survival by histotype and disease stage","volume":"111","author":"Peres","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"B27","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/s1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1203648","DOI":"10.3389\/fphar.2023.1203648","article-title":"Development of evidence-based indicators for the detection of drug-related problems among ovarian cancer patients","volume":"14","author":"Rawal","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B31","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","article-title":"Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial","volume":"34","author":"Ray-Coquard","year":"2023","journal-title":"Ann. Oncol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"9","DOI":"10.20892\/j.issn.2095-3941.2016.0084","article-title":"Epidemiology of ovarian cancer: a review","volume":"14","author":"Reid","year":"2017","journal-title":"Cancer Biol. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1007\/s00228-020-02909-w","article-title":"Borrowing external information to improve Bayesian confidence propagation neural network","volume":"76","author":"Tada","year":"2020","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1080\/14740338.2024.2390640","article-title":"Cardiovascular adverse events associated with PARP inhibitors for ovarian cancer: a real world study (RWS) with Bayesian disproportional analysis based on the FDA adverse event reporting system (FAERS)","volume":"24","author":"Yang","year":"","journal-title":"Expert Opin. Drug Saf."},{"key":"B36","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.clinthera.2025.04.016","article-title":"Peripheral neuropathy in patients with ovarian cancer administrating poly ADP-ribose polymerase inhibitors: a real-world study based on Bayesian disproportionality analysis of the US food and drug administration adverse event reporting system","volume":"47","author":"Yang","year":"","journal-title":"Clin. Ther."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1582050","DOI":"10.3389\/fimmu.2025.1582050","article-title":"Adverse drug reaction assessment of pembrolizumab in cervical cancer treatment: a real-world pharmacovigilance study using the FAERS database","volume":"16","author":"Zhang","year":"","journal-title":"Front. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"1589841","DOI":"10.3389\/fbioe.2025.1589841","article-title":"Bevacizumab in ovarian cancer therapy: current advances, clinical challenges, and emerging strategies","volume":"13","author":"Zhang","year":"","journal-title":"Front. Bioeng. Biotechnol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1867038\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T06:19:04Z","timestamp":1782195544000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1867038\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,23]]},"references-count":38,"alternative-id":["10.3389\/fphar.2026.1867038"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1867038","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,23]]},"article-number":"1867038"}}